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Introduction:  Retroperitoneal fibrosis (RPF) is a rare inflammatory disease resulting in the development of
a retroperitoneal mass, which may encase the aorta and its branches, as well as the ureters.
Observation:  The systemic inflammatory response causes constitutional symptoms. The mass itself leads
to symptoms of non-specific back pain and abdominal pain, as well as ureteric obstruction and subsequent
renal insufficiency. Immunoglobulin 4 (IgG4) has recently been found to be involved in the pathogenesis
of multiple autoimmune and inflammatory disorders, including RPF. Blood work-up, imaging and biopsy
of the mass remain the mainstay of diagnosis.
Conclusion:  RPF remains a diagnosis of exclusion. Treatment hinges on corticosteroids, but other immuno-
suppressants and disease-modifying agents are also being used more commonly. Surgical intervention is
only carried out when conservative measures have failed or are contraindicated, and in order to preserve
renal function.








etroperitoneal fibrosis (RPF) is a systemic inflammatory disease
esulting in retroperitoneal plaque formation. This mass is initially
nflammatory in nature, and later evolves into a fibrotic mass [1].∗ Corresponding author at: PO Box 727, Howard Place, 7450 Cape Town,
outh Africa.
-mail address: farzanac@icloud.com (F. Cassim).






110-5704/© 2016 Pan African Urological Surgeons’ Association. Production anhe estimated incidence varies between 0.1 in 100 000 and 1 per
00 000 in different studies, but little epidemiological data exists to
onfirm or refute this [1]. Much controversy surrounds the diagnosis
nd treatment of this disease. With this case report, we wish to
ighlight a patient with immunoglobulin-mediated RPF confirmed
n histology.ase  report
 56-year-old male, with no known comorbidities, presented with
ight flank pain. The patient was found to have microscopic
d hosting by Elsevier B.V. All rights reserved.


































Fig.  1  (a) Mass at the level of the renal hilum. (b) Mass at the level
of the renal hilum – nephrostomy visible in proximal ureter.
haematuria on urine dipsticks on admission, as well as abnormal
renal function, with a creatinine of 134 mol/L. The erythrocyte
sedimentation rate (ESR) was 60, with a white cell count (WCC) of
7.2 ×  109.
On renal ultrasound, the patient was found to have right-sided
hydronephrosis and proximal hyroureter. The patient then under-
went an uncontrasted computer-tomography (CT) scan of his
abdomen and pelvis in order to assess for a cause for the unilat-
eral hydronephrosis. The CT scan revealed a mass extending from
the level of the renal hilum on the right and encasing the right ureter
as noted in Fig. 1.
A right percutaneous nephrostomy tube was inserted as an emer-
gency, and the patient’s renal function subsequently decreased to
109 mol/L. A double-J (DJ) ureteric stent was placed (antegrade)
while pending further work-up. The patient was also started on high-
dose oral glucocorticoid therapy due to the CT features and raised
ESR suggesting RPF. Despite ureteric stenting and glucocorticoid
therapy, it was not possible to remove the percutaneous nephros-
tomy tube. During attempted clamping of the nephrostomy tube,
the patient experienced pain relieved only by unclamping of the






ig.  2  Right ureter mobilised with omentum to be used for wrapping
reter.
iagnostic and therapeutic laparoscopy was performed in view of
he ongoing obstructive uropathy despite ureteral stenting and gluco-
orticoid therapy. The mass was noted to resemble an inflammatory
laque, and frozen section specimens were sent intra-operatively.
he results of frozen section revealed inflammatory tissue, with
o features of malignancy. Ureterolysis was performed, whereby
he ureter was released from the inflammatory plaque and wrapped
n omentum, as seen in Fig. 2. Unfortunately, it was necessary to
onvert to laparotomy due to challenges with tissue planes and the
roximity of vital structures to the obstructed portion of the ureter.
he percutaneous nephrostomy tube, as well as the DJ stent
ere both removed within 6 weeks of the ureterolysis procedure.
he patient has normal renal function and is currently asymp-
omatic. Formal histology confirmed the diagnosis of IgG4-related
etroperitoneal fibrosis with extensive collagenous fibrosis, dense
ymphoplasmacytic chronic inflammation, obliterative phlebitis
Fig. 3a), and >30 IgG4+ plasma cells per high power field (Fig. 3b).
iscussion
PF was first described by Ormond in 1948 [2]. The classical
escription is that of a retroperitoneal plaque encasing the great ves-
els and the ureters from the level of the renal hilum up to the pelvis
1]. Seventy percent of these cases are idiopathic in nature, with
he other 30% having an underlying precipitating cause [1,3]. The
ost important of these underlying causes that a treating physician
ust rule out is a malignant process. Malignancy has been found
n 8–10% of cases of patients with RPF [1]. Other precipitants are
ocumented in Table 1 [1,4].
ther disease processes that may be associated with RPF, but not






 Systemic lupus erythematosis
64 
Fig.  3  (a) Fibrous obliteration of the lumen of a small vein, the wall
of which is infiltrated by lymphocytes and plasma cells (haematoxylin
and eosin stain, high power magnification). (b) Numerous IgG4+ plasma
cells (immunohistochemical stain for IgG4, high power magnification).












◦ Inflammatory bowel disease
• Retroperitoneal haemorrhage
◦ Abdominal and pelvic surgery
◦ Ruptured viscera (Trauma)
◦ Henoch-Schonlein Purpura
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atients present with a variety of non-specific symptoms. These
nclude abdominal or back pain, fever, malaise, loss of weight,
nd may develop new-onset hypertension, as well as obstructive
ropathy [1,4].
nvestigations include blood work-up, with a serum creatinine, a
CC and an ESR as the initial tests to be performed [1,3]. These
re non-specific tests, but RPF tends to be associated with raised
nflammatory markers, including a high ESR, as well as a raised
-reactive protein (CRP) level [1,5]. Other blood tests that may
e considered include those for autoimmunity work-up, such as
nti-double-stranded DNA, anti-nuclear antibody, anti-neutrophil
ytoplasmic antibodies, and recently, raised IgG4 levels. IgG4 lev-
ls have been found to be increased with RPF, and a IgG4:total
gG has also been proved to be useful in that a higher ratio con-
rms the diagnosis [6]. Serum IgG4 levels may or may not be
aised. These patients also tend to present with features of autoim-
une disease as opposed to the classical symptoms associated with
PF, including constitutional symptoms alone, generalised painless
ymphadenopathy, autoimmune pancreatitis and sialadenitis [7,8].
enal dysfunction in these patients may also be caused by IgG4-
elated tubulo-interstitial nephritis, as opposed to the obstruction
rom RPF itself [9].
t is becoming apparent that more cases that were previously labelled
diopathic RPF are actually IgG4-related RPF [9,10]. The true
mportance of this finding is yet to be confirmed. However, given that
any patients with IgG4-related RPF have associated autoimmune
ymptoms, it is important to specifically look for these symptoms
n order to optimise overall patient care. Treatment is currently still
lucocorticoid-based, but with further investigations it may be found
hat it may be more useful to use B-cell depletion therapy (e.g.
ituximab) for these cases [8].
n imaging, CT scan and magnetic resonance imaging (MRI) are
onsidered to be the most sensitive and specific for RPF [3,6].
he classical appearance of RPF on a CT scan is a centrally sit-
ated retroperitoneal plaque from the level of the renal hilum and
xtending distally until the aortic bifurcation at the level of the
acral promontory [1,6]. A patient with the afore-mentioned clin-
cal presentation, a raised ESR on blood work-up, and a CT scan
uggestive of the diagnosis may be treated empirically as RPF with-
ut biopsy. However, any atypia in the presentation or work-up
hould alert one to the possibility of a retroperitoneal malignant pro-
ess. This warrants biopsy by either percutaneous or opens means
1].
edical management includes the use of high-dose steroids initially,
nd then tapering to chronic low-dose continuation therapy [1,11].
owever, much controversy exists regarding the optimal dosage
nd dosing schedule. One regimen that has been suggested involves
sing 60 mg of prednisolone on alternate days for 2 months, and
hen tapering down to 5 mg on alternate days over the following
 months [11]. There are many options that have been tried, each
ith varying levels of success. A successful treatment regimen is
egarded as improved symptoms, as well as regression of the mass
nd normalisation of the ESR [1,11]. Other methods of medical man-
gement have been used, including: azathriprine, mycophenolate
ofetil, tamoxifen, and pulses of methylprednisolone [3,4,6,12].
ituximab has been used for IgG4-related disease in an off-label
apacity [8]. Due to the rare nature of the disease, and the vari-












surgical and/or medical approaches. Nephrol Dial Transplant 2006;21:An atypical cause of retroperitoneal fibrosis: A case report and liter
which treatment regimen is optimal. Follow-up routines also vary,
but include symptom assessment and ESR monitoring every 3–6
months, and possibly CT scan follow-up to assess for regression of
the mass [11].
Surgical management plays a role in medically refractory cases, as
well as in cases where medical therapy is not tolerated or contra-
indicated [1]. Surgical management involves biopsy of the mass,
as well as ureterolysis (release of the ureters from the plaque) with
intra-peritonealisation and wrapping in omentum [1,13]. This pre-
vents further entrapment of the ureters should the process progress
or recur. One criticism of surgical management is that it does not
manage the systemic symptoms of the disease process [12].
Conclusion
RPF is an uncommon disease process that is difficult to diagnose and
requires a high index of suspicion in order to facilitate expeditious
diagnosis and management. Atypical presenting features such as a
unilateral mass, as seen with our patient, must raise the question
of malignancy requiring full work-up to exclude this possibility.
This case also highlights autoimmune entities, such as IgG4-related
disease, that may be a part of the pathogenesis of the disease process.
These entities should be sought as they may influence management
protocols in the future. Medical management is currently regarded
as first-line treatment of choice, but surgical management may be
necessary in selected patients. Further studies with regards to the
aetiology of RPF are needed so as to optimise patient care.
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